FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200193150> ?p ?o ?g. }

• W4200193150 endingPage "76" @default.
• W4200193150 startingPage "65" @default.
• W4200193150 abstract "Despite recent advances in therapeutic options, there remains an unmet need for treating patients with relapsed or refractory multiple myeloma, especially in those previously exposed or refractory to lenalidomide. This updated efficacy and safety analysis from the phase 3 CANDOR study compared carfilzomib, daratumumab, and dexamethasone (KdD) with carfilzomib and dexamethasone (Kd) in patients with relapsed or refractory multiple myeloma.In this updated analysis of the randomised, multicentre, open-label, phase 3 CANDOR study, patients (aged ≥18 years) with relapsed or refractory multiple myeloma, at least a partial response to between one and three previous therapies, and Eastern Cooperative Oncology Group performance status of 0-2, were recruited from 102 medical centres globally and randomly assigned (2:1) by interactive voice or web response software to receive KdD or Kd. Participants were stratified by disease stage, previous proteasome inhibitor or anti-CD38 antibody exposure, and number of previous therapies. All patients received intravenous infusions of carfilzomib twice per week at 56 mg/m2 (20 mg/m2 on days 1 and 2 during cycle 1) on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. Daratumumab (8 mg/kg) was administered intravenously on days 1 and 2 of cycle 1 and at 16 mg/kg weekly for the remaining doses of the first two cycles, then every 2 weeks for four cycles (cycles 3-6), and every 4 weeks thereafter. Patients received 40 mg dexamethasone weekly (20 mg for patients >75 years old). This analysis was a preplanned interim analysis for overall survival; however, at the time of data cutoff, overall survival data were not mature. The primary endpoint was progression-free survival. Here, we provide updated progression-free survival data, assessed centrally by Onyx Response Computer Algorithm in the intention-to-treat population, with 11 months additional follow-up. Adverse events were assessed in the safety population, which included all participants who received at least one dose of trial treatment. CANDOR is registered with ClinicalTrials.gov, NCT03158688, and is active but not recruiting.Between June 13, 2017, and June 25, 2018, 466 patients were enrolled, of whom 312 received KdD and 154 received Kd. At data cutoff (June 15, 2020), median follow-up was 27·8 months (IQR 25·6-29·5) for KdD and 27·0 months (13·2-28·6) for Kd. Median progression-free survival was 28·6 months (95% CI 22·7-not estimable [NE]) in the KdD group and 15·2 months (11·1-19·9) in the Kd group (hazard ratio 0·59 [95% CI 0·45-0·78], log-rank p<0·0001). Treatment-emergent adverse events in the safety population were consistent with the primary analysis. Grade 3 or worse treatment-emergent adverse events occurred in 268 (87%) patients in the KdD group and 116 (76%) in the Kd group; most commonly thrombocytopenia (76 [25%] vs 25 [16%], respectively), hypertension (65 [21%] vs 23 [15%]), pneumonia (54 [18%] vs 14 [9%]), and anaemia (53 [17%] vs 23 [15%]). Serious adverse events occurred in 194 (63%) patients with KdD and 76 (50%) with Kd. Adverse events leading to death occurred in 27 (9%) patients in the KdD group and seven (5%) in the Kd group; most commonly septic shock (five [2%] vs one (1%]) and pneumonia (four [1%] vs none). No new treatment-related deaths have occurred since the primary analysis.A clear, maintained progression-free survival benefit of KdD over Kd with longer follow-up was confirmed, making KdD an emerging standard-of-care for patients with relapsed or refractory multiple myeloma.Amgen and Janssen." @default.
• W4200193150 created "2021-12-31" @default.
• W4200193150 creator A5004781025 @default.
• W4200193150 creator A5010388094 @default.
• W4200193150 creator A5017190714 @default.
• W4200193150 creator A5019519345 @default.
• W4200193150 creator A5022520524 @default.
• W4200193150 creator A5022522496 @default.
• W4200193150 creator A5023752321 @default.
• W4200193150 creator A5029159537 @default.
• W4200193150 creator A5048560248 @default.
• W4200193150 creator A5054952877 @default.
• W4200193150 creator A5056175074 @default.
• W4200193150 creator A5057911528 @default.
• W4200193150 creator A5074006851 @default.
• W4200193150 creator A5080776694 @default.
• W4200193150 creator A5082004555 @default.
• W4200193150 creator A5083639923 @default.
• W4200193150 creator A5088691462 @default.
• W4200193150 creator A5091396091 @default.
• W4200193150 date "2022-01-01" @default.
• W4200193150 modified "2023-10-11" @default.
• W4200193150 title "Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study" @default.
• W4200193150 cites W1577036326 @default.
• W4200193150 cites W1988265934 @default.
• W4200193150 cites W2588162473 @default.
• W4200193150 cites W2775001520 @default.
• W4200193150 cites W2843165346 @default.
• W4200193150 cites W2909894833 @default.
• W4200193150 cites W2935332994 @default.
• W4200193150 cites W2945434115 @default.
• W4200193150 cites W2970922094 @default.
• W4200193150 cites W3012570191 @default.
• W4200193150 cites W3028330817 @default.
• W4200193150 cites W3043410628 @default.
• W4200193150 cites W3088063465 @default.
• W4200193150 cites W3094960809 @default.
• W4200193150 cites W3096698499 @default.
• W4200193150 cites W3176913342 @default.
• W4200193150 cites W3211352828 @default.
• W4200193150 doi "https://doi.org/10.1016/s1470-2045(21)00579-9" @default.
• W4200193150 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34871550" @default.
• W4200193150 hasPublicationYear "2022" @default.
• W4200193150 type Work @default.
• W4200193150 citedByCount "62" @default.
• W4200193150 countsByYear W42001931502022 @default.
• W4200193150 countsByYear W42001931502023 @default.
• W4200193150 crossrefType "journal-article" @default.
• W4200193150 hasAuthorship W4200193150A5004781025 @default.
• W4200193150 hasAuthorship W4200193150A5010388094 @default.
• W4200193150 hasAuthorship W4200193150A5017190714 @default.
• W4200193150 hasAuthorship W4200193150A5019519345 @default.
• W4200193150 hasAuthorship W4200193150A5022520524 @default.
• W4200193150 hasAuthorship W4200193150A5022522496 @default.
• W4200193150 hasAuthorship W4200193150A5023752321 @default.
• W4200193150 hasAuthorship W4200193150A5029159537 @default.
• W4200193150 hasAuthorship W4200193150A5048560248 @default.
• W4200193150 hasAuthorship W4200193150A5054952877 @default.
• W4200193150 hasAuthorship W4200193150A5056175074 @default.
• W4200193150 hasAuthorship W4200193150A5057911528 @default.
• W4200193150 hasAuthorship W4200193150A5074006851 @default.
• W4200193150 hasAuthorship W4200193150A5080776694 @default.
• W4200193150 hasAuthorship W4200193150A5082004555 @default.
• W4200193150 hasAuthorship W4200193150A5083639923 @default.
• W4200193150 hasAuthorship W4200193150A5088691462 @default.
• W4200193150 hasAuthorship W4200193150A5091396091 @default.
• W4200193150 hasConcept C121332964 @default.
• W4200193150 hasConcept C126322002 @default.
• W4200193150 hasConcept C142424586 @default.
• W4200193150 hasConcept C143998085 @default.
• W4200193150 hasConcept C2776063141 @default.
• W4200193150 hasConcept C2776364478 @default.
• W4200193150 hasConcept C2778367456 @default.
• W4200193150 hasConcept C2780108899 @default.
• W4200193150 hasConcept C2780401358 @default.
• W4200193150 hasConcept C2781119759 @default.
• W4200193150 hasConcept C535046627 @default.
• W4200193150 hasConcept C61943457 @default.
• W4200193150 hasConcept C71924100 @default.
• W4200193150 hasConcept C87355193 @default.
• W4200193150 hasConceptScore W4200193150C121332964 @default.
• W4200193150 hasConceptScore W4200193150C126322002 @default.
• W4200193150 hasConceptScore W4200193150C142424586 @default.
• W4200193150 hasConceptScore W4200193150C143998085 @default.
• W4200193150 hasConceptScore W4200193150C2776063141 @default.
• W4200193150 hasConceptScore W4200193150C2776364478 @default.
• W4200193150 hasConceptScore W4200193150C2778367456 @default.
• W4200193150 hasConceptScore W4200193150C2780108899 @default.
• W4200193150 hasConceptScore W4200193150C2780401358 @default.
• W4200193150 hasConceptScore W4200193150C2781119759 @default.
• W4200193150 hasConceptScore W4200193150C535046627 @default.
• W4200193150 hasConceptScore W4200193150C61943457 @default.
• W4200193150 hasConceptScore W4200193150C71924100 @default.
• W4200193150 hasConceptScore W4200193150C87355193 @default.
• W4200193150 hasIssue "1" @default.
• W4200193150 hasLocation W42001931501 @default.
• W4200193150 hasLocation W42001931502 @default.
• W4200193150 hasOpenAccess W4200193150 @default.

• next